JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB

JPMorgan Chase & Co. grew its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 17.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 933,309 shares of the company’s stock after buying an additional 135,814 shares during the quarter. JPMorgan Chase & Co. owned 0.15% of Genmab A/S worth $19,282,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Orbis Allan Gray Ltd lifted its holdings in Genmab A/S by 102.8% in the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock valued at $111,816,000 after acquiring an additional 2,895,179 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock valued at $24,634,000 after purchasing an additional 665,893 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Genmab A/S by 111.5% in the 1st quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company’s stock valued at $21,149,000 after purchasing an additional 569,345 shares during the period. ABC Arbitrage SA purchased a new stake in Genmab A/S during the second quarter worth $9,236,000. Finally, Eagle Global Advisors LLC acquired a new stake in Genmab A/S during the first quarter valued at $4,098,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on GMAB shares. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. Finally, HC Wainwright increased their target price on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $32.02 on Friday. The stock has a market capitalization of $20.57 billion, a P/E ratio of 13.63, a PEG ratio of 1.65 and a beta of 0.90. The business has a 50 day simple moving average of $30.78 and a two-hundred day simple moving average of $25.83. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $33.65.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. As a group, research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.